<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-156148" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cangrelor</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Awosika</surname>
            <given-names>Ayoola O.</given-names>
          </name>
          <aff>University of Illinois College of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ayoola Awosika declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>23</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-156148.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Cangrelor, a potent intravenous antiplatelet agent, has been approved by the U.S. Food and Drug Administration (FDA) for its use in specific patient populations undergoing percutaneous coronary intervention (PCI). The drug's efficacy in reducing thrombotic events during and after PCI is attributed to its unique mechanism of action, pharmacokinetics, and pharmacodynamics. Although cangrelor is generally well tolerated, healthcare professionals must be aware of the potential adverse drug reactions (ADRs), drug interactions, contraindications, and managing overdose related to cangrelor. This therapeutic review aims to provide an in-depth analysis of cangrelor, encompassing its indications, FDA approval, off-label uses, mechanism of action, pharmacokinetics, pharmacodynamics, and ADRs. Moreover, this activity also highlights the crucial role of interprofessional collaboration in enhancing patient outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate indications for cangrelor therapy in patients undergoing percutaneous coronary intervention.</p></list-item><list-item><p>Apply evidence-based guidelines and best practices when selecting cangrelor as an antiplatelet therapy option.</p></list-item><list-item><p>Assess the potential risks and complications related to cangrelor therapy.</p></list-item><list-item><p>Screen patients for contraindications, potential drug interactions, and individual risk factors influencing cangrelor therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=156148&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=156148">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-156148.s2" sec-type="Indications">
        <title>Indications</title>
        <p>The U.S. Food and Drug Administration (FDA) approved cangrelor in June 2015, following comprehensive data from the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) trials. These trials involved approximately 25,000 patients and demonstrated the drug's remarkable efficacy and use in patient populations undergoing percutaneous coronary intervention (PCI).<xref ref-type="bibr" rid="article-156148.r1">[1]</xref></p>
        <p>Cangrelor is the only direct parental P2Y<sub>12</sub> receptor inhibitor currently available, with a rapid onset and offset of action&#x000a0;in contrast to oral P2Y<sub>12</sub> inhibitors such as clopidogrel, prasugrel, and ticagrelor.<xref ref-type="bibr" rid="article-156148.r2">[2]</xref>&#x000a0;This drug is primarily used in patients undergoing PCI, a procedure for treating coronary artery disease.<xref ref-type="bibr" rid="article-156148.r3">[3]</xref>&#x000a0;</p>
        <p>Cangrelor is used as adjunctive antiplatelet therapy&#x000a0;for patients undergoing PCI to reduce the risk of thrombotic events during and after the procedure. This treatment is especially beneficial for high-risk patients or those not receiving adequate pretreatment with oral antiplatelet agents.<xref ref-type="bibr" rid="article-156148.r4">[4]</xref></p>
        <p>The FDA has approved cangrelor for the following indications:</p>
        <list list-type="bullet">
          <list-item>
            <p>Prevention of periprocedural myocardial infarction (MI). Cangrelor helps mitigate the risk of periprocedural MI, a potentially life-threatening condition, during the PCI procedure.<xref ref-type="bibr" rid="article-156148.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Prevention of stent thrombosis. Cangrelor effectively reduces the incidence of stent thrombosis, defined as a thrombotic occlusion of a coronary stent, thereby helping to prevent further cardiovascular complications.<xref ref-type="bibr" rid="article-156148.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Prevention of repeat coronary revascularization. Cangrelor therapy helps prevent the need for additional coronary revascularization procedures by effectively reducing the occurrence of restenosis (the narrowing again of the treated artery).<xref ref-type="bibr" rid="article-156148.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>Clinicians and patients must understand that cangrelor is designed for short-term use exclusively during the PCI procedure and the immediate post-procedural period.&#x000a0;This drug is not intended for long-term maintenance therapy and should be bridged with oral antiplatelet agents after hospital admission to ensure optimal treatment continuity and patient safety.&#x000a0;As per the American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography &#x00026; Interventions (ACC/AHA/SCAI) guidelines, intravenous (IV) cangrelor can be&#x000a0;a viable option for patients undergoing PCI who have not been previously exposed to P2Y<sub>12</sub> inhibitors for&#x000a0;reducing&#x000a0;periprocedural ischemic events.<xref ref-type="bibr" rid="article-156148.r8">[8]</xref></p>
        <p>
<bold>Off-Label Use</bold>
</p>
        <p>In addition to its approved indications, cangrelor is also used as a bridging agent in patients who have recently undergone stent implantation and require cardiac surgery.<xref ref-type="bibr" rid="article-156148.r9">[9]</xref></p>
      </sec>
      <sec id="article-156148.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Cangrelor, a novel nonthienopyridine adenosine triphosphate (ATP) analog, exerts its antiplatelet effects through a specific mechanism of action. This medication functions by inhibiting blood platelet activation and aggregation, ultimately reducing the risk of thrombotic events.</p>
        <p>The primary mechanisms of action of cangrelor are&#x000a0;listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>P2Y<sub>12</sub> receptor antagonism: Cangrelor is a reversible antagonist of the P2Y<sub>12</sub> receptor, an essential receptor involved in platelet activation and aggregation. By binding to the P2Y<sub>12</sub> receptor on platelets, cangrelor effectively blocks the binding of adenosine diphosphate (ADP), a potent platelet activator (see <bold>Image.&#x000a0;</bold>Cangrelor Mechanism of Action). This action leads to inhibiting the ADP-mediated signaling pathway and subsequent platelet activation.&#x000a0;<xref ref-type="bibr" rid="article-156148.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Rapid onset and offset of action: Cangrelor exhibits a rapid onset of action, reaching maximum platelet inhibition within minutes of administration. This quick onset&#x000a0;renders the drug particularly useful in the acute setting of PCI, where immediate platelet inhibition is essential. Moreover, cangrelor's effects are quickly reversible upon discontinuation, leading to a shorter duration of action than other antiplatelet agents.<xref ref-type="bibr" rid="article-156148.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Platelet inhibition without requiring metabolism: Unlike oral antiplatelet agents, such as clopidogrel or ticagrelor, cangrelor&#x000a0;does not rely on metabolic activation within the body.&#x000a0;Cangrelor is administered as an IV infusion directly into the bloodstream, eliminating the need for hepatic metabolism. This unique characteristic of cangrelor&#x000a0;ensures consistent platelet inhibition without interpatient variability.</p>
          </list-item>
          <list-item>
            <p>Preservation of vascular function: Cangrelor exhibits selective inhibition of the P2Y<sub>12</sub> receptor on platelets while leaving other ADP receptors unaffected. This selectivity helps preserve endothelial function and maintain the balance between antithrombotic effects and the physiological hemostatic response. In addition, it enables platelet inhibition without compromising the overall integrity of the vascular system.</p>
          </list-item>
        </list>
        <p>In summary, cangrelor is a potent and reversible intravenous P2Y12 inhibitor, which acts directly and has a short duration of action. Cangrelor quickly inhibits platelet function upon administration and restores normal platelet function within&#x000a0;1 hour of discontinuation.</p>
        <p>According to ACC/AHA/SCAI guidelines, cangrelor leads to predictable, rapid, and profound inhibition of platelets. This action makes cangrelor effective in preventing stent thrombosis, especially in patients not pretreated with a P2Y<sub>12</sub> inhibitor. In addition, cangrelor proves beneficial in situations where the absorption of oral medications is inadequate.<xref ref-type="bibr" rid="article-156148.r8">[8]</xref></p>
        <p>A meta-analysis of CHAMPION-PCI, CHAMPION-PLATFORM, and CHAMPION-PHOENIX trials provided substantial support for these observations, indicating a decreased incidence of the combined outcome of death, MI, revascularization driven by ischemia, or stent thrombosis within 48 hours with the use of cangrelor compared to clopidogrel. Furthermore, cangrelor exhibited a remarkable 41% reduction in the occurrence of stent thrombosis. Although significant bleeding events were comparable between the two cohorts, there was a higher frequency of minor bleeding in the cangrelor group.<xref ref-type="bibr" rid="article-156148.r12">[12]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>Understanding the pharmacokinetic profile of cangrelor is essential for appropriate dosing, monitoring, and optimizing therapeutic outcomes.</p>
        <p>The key aspects of the cangrelor's pharmacokinetics are as follows:</p>
        <p>Route of administration: Cangrelor is administered intravenously as a continuous infusion. The&#x000a0;IV route&#x000a0;enables rapid and predictable drug delivery, ensuring immediate platelet inhibition during and after PCI.<xref ref-type="bibr" rid="article-156148.r13">[13]</xref></p>
        <p>Absorption: As cangrelor is administered intravenously, it is fully and immediately available in the systemic circulation, bypassing the need for absorption from the gastrointestinal tract, leading to peak plasma concentration within 2 minutes of its administration.</p>
        <p>Distribution: Cangrelor exhibits rapid distribution throughout the bloodstream, facilitated by its high-water solubility and a volume of distribution of 3.9 L. Approximately 97% to 98% of the drug binds to protein. Notably, cangrelor binds extensively to platelets, primarily through the P2Y<sub>12</sub> receptor, enabling it to reach its site of action and exert potent antiplatelet effects.</p>
        <p>Metabolism: Cangrelor undergoes primary metabolism through non-enzymatic hydrolysis in the blood plasma via dephosphorylation. This rapid and spontaneous degradation leads to the formation of an inactive metabolite. This metabolism occurs independently of hepatic enzymes and does not involve the cytochrome P450 system.</p>
        <p>Elimination: Cangrelor and its metabolite are primarily eliminated through renal excretion, with a plasma clearance of about 43 L/h. The elimination half-life of cangrelor is relatively short, averaging about 3 to 6 minutes.<xref ref-type="bibr" rid="article-156148.r14">[14]</xref> This short half-life allows rapid drug elimination, rendering it&#x000a0;suitable for situations&#x000a0;for prompt platelet inhibition.</p>
        <p>Clinical implications: The favorable pharmacokinetic profile of cangrelor, characterized by its short half-life and rapid reversibility, holds significant clinical implications. Healthcare professionals can benefit from its predictable and controllable pharmacokinetics, enabling them to adjust and titrate the infusion rate as needed during PCI procedures.</p>
      </sec>
      <sec id="article-156148.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Cangrelor is available in a parenteral dosage form, specifically as a lyophilized powder for IV infusion. The lyophilized powder is reconstituted with a suitable diluent to prepare a solution for IV administration.&#x000a0;Cangrelor is typically supplied in vials or single-use infusion bags.</p>
        <p>
<bold>Available Dosage Forms</bold>
</p>
        <p>Cangrelor is available in an IV infusion form.</p>
        <p>
<bold>Strength</bold>
</p>
        <p>The available strength of cangrelor is 50 mg per vial.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>Loading dose: A loading dose of cangrelor is usually administered before starting the infusion to ensure a rapid onset of platelet inhibition. The recommended loading dose of cangrelor is 30 mcg/kg, given as a bolus injection over a short duration, such as 1 minute.<xref ref-type="bibr" rid="article-156148.r15">[15]</xref></p>
        <p>Continuous infusion: Following the loading dose, a continuous infusion of cangrelor is initiated. The infusion rate is adjusted according to the patient's weight to maintain therapeutic platelet inhibition. The recommended infusion rate of 4 mcg/kg/min allows for a continuous administration of cangrelor throughout the PCI procedure and up to 2 hours after the procedure.</p>
        <p>Adjustment of dosing: The infusion rate of cangrelor can be adjusted based on individual patient factors, such as response to therapy, bleeding risk, and the complexity of the PCI procedure. Dosing may need to be titrated up or down to achieve the desired level of platelet inhibition while carefully managing the risk of bleeding complications.</p>
        <p>Duration of therapy: Cangrelor therapy is typically limited to the duration of the PCI procedure and the immediate post-procedural period. Upon completion of the PCI procedure, patients are often transitioned to oral antiplatelet agents, such as clopidogrel (600 mg), ticagrelor (180 mg), or prasugrel (60 mg), for long-term maintenance therapy.<xref ref-type="bibr" rid="article-156148.r16">[16]</xref><xref ref-type="bibr" rid="article-156148.r17">[17]</xref></p>
        <p>
<bold>Specific Patient Population</bold>
</p>
        <p>Hepatic impairment: Cangrelor has not been specifically studied in patients with hepatic impairment. As the metabolism of cangrelor is not&#x000a0;dependent on hepatic function, dosage adjustment is not necessary for patients with hepatic impairment.<xref ref-type="bibr" rid="article-156148.r18">[18]</xref></p>
        <p>Renal impairment: Typically, no dosage adjustment is necessary for patients with mild, moderate, or severe renal impairment when using cangrelor. However, close monitoring for potential adverse effects and platelet inhibition response is strongly recommended.</p>
        <p>Pregnancy considerations: Limited clinical data exists regarding the use of cangrelor during pregnancy. In pregnant patients requiring intervention, IV heparin is the preferred anticoagulant.<xref ref-type="bibr" rid="article-156148.r19">[19]</xref> As the safety of cangrelor for both the mother and the developing fetus has not been established, its use during pregnancy should be avoided unless the potential benefits outweigh the risks.</p>
        <p>Breastfeeding considerations:&#x000a0;Limited data exist on the excretion of cangrelor in human milk and its potential effects on breastfed infants. Therefore, caution should be exercised when considering the use of cangrelor during lactation.<xref ref-type="bibr" rid="article-156148.r18">[18]</xref></p>
        <p>Pediatric patients:&#x000a0;The safety and effectiveness of cangrelor have not been established in the pediatric population.&#x000a0;</p>
        <p>Geriatric patients: Typically, no dosage adjustment is required for geriatric patients. Patients 75 and older have a higher risk of experiencing moderate-to-severe bleeding, which is approximately 3 times greater than younger patients. However, compared to clopidogrel, cangrelor provides comparable effectiveness in patients both older and younger than&#x000a0;75 without raising the chances of significant bleeding.<xref ref-type="bibr" rid="article-156148.r20">[20]</xref></p>
      </sec>
      <sec id="article-156148.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Like&#x000a0;other medications, cangrelor can potentially cause adverse drug reactions (ADRs) in some patients.<xref ref-type="bibr" rid="article-156148.r21">[21]</xref></p>
        <p>The following is a list of some common ADRs associated with the use of cangrelor.</p>
        <list list-type="bullet">
          <list-item>
            <p>Bleeding: The most common adverse effect of cangrelor is bleeding, ranging from minor events, such as nosebleeds or bruising, to more severe bleeding events. These bleeding events may occur at the site of vascular access, surgical sites, or other locations in the body.</p>
          </list-item>
          <list-item>
            <p>Thrombocytopenia:&#x000a0;Cangrelor can lead to thrombocytopenia, which may increase the risk of bleeding.<xref ref-type="bibr" rid="article-156148.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Hypersensitivity reactions: Cangrelor may lead to hypersensitivity or allergic reactions in&#x000a0;some patients, which may present as skin rash, itching, hives, or swelling.</p>
          </list-item>
          <list-item>
            <p>Nausea and vomiting: Cangrelor may cause gastrointestinal symptoms in some patients, such as nausea and vomiting.</p>
          </list-item>
          <list-item>
            <p>Hypotension: Cangrelor can potentially lower the blood pressure in patients, which may lead to hypotension. Therefore,&#x000a0;healthcare professionals should closely monitor patients' blood pressure during cangrelor administration.</p>
          </list-item>
          <list-item>
            <p>Local site reactions: In certain instances, patients may experience local site reactions at the injection or infusion site, including pain, redness, or swelling.</p>
          </list-item>
        </list>
        <p>
<bold>Drug Interactions</bold>
</p>
        <p>
<bold>Glycoprotein IIb/IIIa Inhibitors</bold>
</p>
        <p>Cangrelor should not be coadministered with glycoprotein IIb/IIIa inhibitors, such as abciximab, eptifibatide, or tirofiban, as this&#x000a0;combination may increase bleeding risk.<xref ref-type="bibr" rid="article-156148.r23">[23]</xref></p>
        <p>
<bold>P2Y<sub>12</sub>&#x000a0;Inhibitors</bold>
</p>
        <p>Cangrelor should be used cautiously with other P2Y<sub>12</sub> inhibitors, such as clopidogrel, ticagrelor, and prasugrel. Cangrelor is known for its high P2Y<sub>12</sub> receptor affinity, which prevents other&#x000a0;P2Y<sub>12</sub> agents from binding to the receptor. Consequently, there is a concern that if additional P2<sub>12</sub> inhibitors are administered during cangrelor infusion, the other drugs (or their metabolites) will be unable to bind to the P2Y<sub>12</sub> receptor, resulting in a lack of antiplatelet effects and ischemic protection.<xref ref-type="bibr" rid="article-156148.r9">[9]</xref>&#x000a0;</p>
        <p>Specific recommendations for switching from IV cangrelor to oral P2Y<sub>12</sub> inhibitors are listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Clopidogrel: During cangrelor infusion, the high receptor occupancy prevents the binding of clopidogrel's active metabolite to the P2Y<sub>12</sub> receptor, leading to a lack of platelet inhibitory effect. Clopidogrel is administered at the end of the cangrelor infusion to avoid this interaction, allowing sufficient time for cangrelor to wash out from the system and subsequent binding of clopidogrel's active metabolite to the&#x000a0;P2Y<sub>12</sub>&#x000a0;receptor. Therefore, it is recommended to administer clopidogrel after the discontinuation of cangrelor infusion to avoid drug interactions.<xref ref-type="bibr" rid="article-156148.r24">[24]</xref></p>
          </list-item>
          <list-item>
            <p>Ticagrelor: Due to its extended systemic half-life and that of its major metabolite, ticagrelor can be safely administered at any time, whether it be before, during, or after cangrelor infusion, without significant drug interactions. A recent clinical trial, known as The Switching Antiplatelet (SWAP)-5 Study, specifically investigated the use of cangrelor in patients pretreated with ticagrelor. Results indicated that administering cangrelor to patients pretreated with ticagrelor enhanced platelet inhibition without any noticeable differences in pharmacokinetic or pharmacodynamic profiles upon discontinuing the drug infusion. Moreover, this study observed no significant drug interactions between cangrelor and ticagrelor.<xref ref-type="bibr" rid="article-156148.r25">[25]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Prasugrel:&#x000a0;The transition from cangrelor to prasugrel should occur after the infusion discontinues&#x000a0;to avoid potential drug interactions. For an effective&#x000a0;transition, initiating the shift approximately 30 minutes before the cangrelor infusion is completed is advisable.<xref ref-type="bibr" rid="article-156148.r26">[26]</xref>&#x000a0;International expert consensus recommends early administration of ticagrelor during&#x000a0;PCI to minimize the potential gap in platelet inhibition during the transition from cangrelor infusion.<xref ref-type="bibr" rid="article-156148.r27">[27]</xref></p>
          </list-item>
        </list>
        <p>In vitro studies have demonstrated that cangrelor does not inhibit the activity of cytochrome P450&#x000a0;enzymes&#x000a0;at therapeutic concentrations. Consequently, the administration of cangrelor is not anticipated to interfere with the hepatic metabolism of other concurrently administered therapeutic agents.<xref ref-type="bibr" rid="article-156148.r28">[28]</xref></p>
        <p>
<bold>Thrombolytic Agents</bold>
</p>
        <p>Cangrelor requires close monitoring and caution when used concomitantly with thrombolytic agents, such as alteplase or reteplase, due to an increased risk of bleeding.<xref ref-type="bibr" rid="article-156148.r29">[29]</xref></p>
        <p>
<bold>Abrocitinib</bold>
</p>
        <p>Cangrelor can potentiate the&#x000a0;antiplatelet effect of abrocitinib. Therefore, the combination of these medications should be avoided.<xref ref-type="bibr" rid="article-156148.r30">[30]</xref></p>
        <p>
<bold>Anticoagulants</bold>
</p>
        <p>The administration of P2Y<sub>12</sub> inhibitors with anticoagulants such as heparin, warfarin, or direct oral anticoagulants may increase the risk of bleeding. Therefore, it is essential to exercise caution when using this combination of medications.<xref ref-type="bibr" rid="article-156148.r31">[31]</xref></p>
      </sec>
      <sec id="article-156148.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Cangrelor is contraindicated in individuals with known hypersensitivity or allergic reactions to cangrelor or its components. Cangrelor is contraindicated in cases of active pathological bleeding, including gastrointestinal bleeding or intracranial hemorrhage.<xref ref-type="bibr" rid="article-156148.r18">[18]</xref></p>
        <p>
<bold>Box Warning</bold>
</p>
        <p>The FDA has issued no specific boxed warnings for cangrelor. However, it&#x000a0;is essential to recognize that drug safety information can evolve over time.</p>
        <p>
<bold>Precautions&#x000a0;</bold>
</p>
        <p>Bleeding risk: Cangrelor increases the risk of bleeding, which can be severe or even life-threatening.<xref ref-type="bibr" rid="article-156148.r32">[32]</xref>&#x000a0;therefore, clinicians should exercise caution when administering cangrelor to patients at an increased risk of bleeding, including those with a recent history of surgery, bleeding disorders, or significant trauma. Close monitoring for signs of bleeding and appropriate management strategies should be implemented to mitigate potential risks and ensure patient safety.</p>
        <p>Thrombocytopenia: Cangrelor can cause a decrease in platelet count, a condition known as thrombocytopenia. Therefore, regular monitoring of platelet counts is recommended, especially during prolonged use or in patients with risk factors for thrombocytopenia.</p>
        <p>Surgical procedures: Cangrelor's antiplatelet effects can prolong bleeding time; therefore, physicians should exercise caution when scheduling surgical procedures. The decision to discontinue cangrelor before surgery should be carefully considered, considering the patient's bleeding risk and the desired duration of the antiplatelet effects.&#x000a0;</p>
        <p>According to the American Society of Regional Anesthesia (ASRA) and Pain Medicine guidelines, the risk of severe bleeding associated with a neuraxial block while the residual effect of cangrelor is present remains unknown. ASRA recommends&#x000a0;removing neuraxial catheters before reinstituting cangrelor therapy postoperatively. The first postoperative dose of cangrelor should be administered 8 hours after the neuraxial catheter has been removed.<xref ref-type="bibr" rid="article-156148.r33">[33]</xref></p>
      </sec>
      <sec id="article-156148.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients receiving cangrelor should be closely monitored for signs of bleeding, both visibly and through laboratory testing (complete blood count). An advanced monitoring technique known as the P2Y<sub>12</sub>&#x000a0;monitoring assay can also be employed. The P2Y<sub>12</sub>&#x000a0;assay estimates the degree of platelet inhibition by P2Y<sub>12</sub> inhibitors, such as cangrelor. The normal reference range for P2Y<sub>12</sub>&#x000a0;reaction units (PRUs) is 194 to 418. However, PRU results may be unreliable in patients with altered hematocrit, platelet counts, or fibrinogen levels. Therefore, it is crucial to monitor hematocrit, platelet count, and fibrinogen levels during cangrelor infusion.<xref ref-type="bibr" rid="article-156148.r34">[34]</xref></p>
      </sec>
      <sec id="article-156148.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Severe toxicity related specifically to cangrelor is rare.<xref ref-type="bibr" rid="article-156148.r35">[35]</xref> Nevertheless, some potential toxicity concerns are associated with cangrelor use, including bleeding, allergic reactions, thrombocytopenia, and local site reactions.&#x000a0;Data on cangrelor overdose were assessed in&#x000a0;a pooled analysis of the CHAMPION trials. The study identified 36 patients who experienced an overdose of cangrelor. In most cases, the cangrelor dose did not exceed 2.5 times the recommended dosage. Notably, only 1 patient who experienced an overdose had a severe bleeding event.<xref ref-type="bibr" rid="article-156148.r36">[36]</xref></p>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Common signs and symptoms of cangrelor overdose include bleeding and thrombocytopenia.</p>
        <p>
<bold>Managing Overdose</bold>
</p>
        <p>Managing cangrelor overdose involves providing supportive care and closely monitoring the patient's condition as no specific antidote is available for the drug.</p>
        <list list-type="bullet">
          <list-item>
            <p>Stop the cangrelor infusion immediately and seek assistance from a rapid response team.<xref ref-type="bibr" rid="article-156148.r37">[37]</xref></p>
          </list-item>
          <list-item>
            <p>Monitor the patient's vital signs, including blood pressure, heart rate, and oxygen saturation.</p>
          </list-item>
          <list-item>
            <p>Perform continuous cardiac monitoring to assess for any arrhythmias or changes in the electrocardiogram.</p>
          </list-item>
          <list-item>
            <p>Consider platelet transfusion&#x000a0;under the guidance of a hematologist in cases of severe bleeding or refractory thrombocytopenia to restore platelet function and aid in clot formation.</p>
          </list-item>
          <list-item>
            <p>Consult&#x000a0;a toxicologist in severe cases for assistance.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-156148.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Interdisciplinary collaboration and effective communication among these healthcare professionals are essential to optimize patient outcomes and ensure the safe use of cangrelor. By working together, they can provide comprehensive care, monitor for potential adverse events, and adjust the treatment plan to achieve the best possible results for the patient.&#x000a0;When cangrelor is administered to a patient, several disciplines may be involved in&#x000a0;treating the patient&#x000a0;and managing their condition.</p>
        <p>The cardiologist plays a central role in the administration of cangrelor, as they are responsible for determining the appropriate indication, dosage, and duration of therapy. In addition, the cardiology&#x000a0;team&#x000a0;monitors the patient's cardiovascular status, assesses the need for antiplatelet therapy, and evaluates the response to treatment.</p>
        <p>Clinical&#x000a0;pharmacists play a crucial role in ensuring the safe and effective use of cangrelor. They provide medication reconciliation, assess potential drug interactions, recommend appropriate dosing adjustments in patients with renal or hepatic impairment, and educate patients on the medication.&#x000a0;Cardiothoracic surgery is required for off-label uses. A hematologist consultation may be necessary for severe bleeding. Pathologist provides valuable input regarding the appropriate laboratory monitoring.&#x000a0;Nursing should&#x000a0;monitor the patient and inform the team regarding any adverse event.&#x000a0;&#x000a0;</p>
        <p>According to the CAMEO registry (Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes), considerable variation in the utilization of cangrelor is evident across different hospitals, with only 27% of patients receiving cangrelor and transitioning to an oral P2Y<sub>12</sub> inhibitor in adherence to the clinical trial and FDA label.</p>
        <p>Additionally, over one-third of patients are administered a cangrelor infusion for a duration shorter than what is recommended by the FDA (&#x0003c;2 h). These results have important clinical implications, emphasizing the need for improvement in P2Y<sub>12</sub> inhibitor transition for individuals undergoing&#x000a0;PCI after experiencing an MI. The strategy suggested is&#x000a0;improving the knowledge and understanding of&#x000a0;clinicians&#x000a0;and pharmacists to facilitate the appropriate utilization and smooth transition of cangrelor to an oral P2Y<sub>12</sub> inhibitor.<xref ref-type="bibr" rid="article-156148.r38">[38]</xref></p>
        <p>Consequently, an interprofessional team approach utilizing open communication and shared decision-making&#x000a0;among clinicians, including specialists, pharmacists, and toxicologists, is essential to improve patient outcomes related to cangrelor therapy.</p>
      </sec>
      <sec id="article-156148.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=156148&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=156148">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/156148/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=156148">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-156148.s11">
        <fig id="article-156148.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Cangrelor Mechanism of Action. The figure depicts platelet receptor antagonist drugs and protease-activated receptors (PAR) and thromboxane receptors (TP). Contributed by Ayoola Awosika, MD. Original design.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Cangrelor__mechanism__of__action" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-156148.s12">
        <title>References</title>
        <ref id="article-156148.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaduganathan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Qamar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Venkateswaran</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Szumita</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Croce</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Mauri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Leopold</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Sobieszczyk</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Faxon</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Cangrelor Use Since FDA&#x000a0;Approval: A Single-Center, Real-World Experience at a Tertiary Care Hospital.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2017</year>
            <month>Jan</month>
            <day>31</day>
            <volume>69</volume>
            <issue>4</issue>
            <fpage>463</fpage>
            <page-range>463-464</page-range>
            <pub-id pub-id-type="pmid">27914699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abubakar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Raza</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Javed</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Farrukh</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Faraz</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Efficacy, Safety, and Role of Antiplatelet Drugs in the Management of Acute Coronary Syndrome: A Comprehensive Review of Literature.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>e36335</fpage>
            <pub-id pub-id-type="pmid">37077602</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alagna</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mazzone</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Contarini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>And&#x000f2;</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Dual Antiplatelet Therapy with Parenteral P2Y<sub>12</sub> Inhibitors: Rationale, Evidence, and Future Directions.</article-title>
            <source>J Cardiovasc Dev Dis</source>
            <year>2023</year>
            <month>Apr</month>
            <day>09</day>
            <volume>10</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">37103042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Hamm</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Leonardi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gallup</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bramucci</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Radke</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Widimsk&#x000fd;</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tousek</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tauth</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Spriggs</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McLaurin</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Angiolillo</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>G&#x000e9;n&#x000e9;reux</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Prats</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Todd</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Skerjanec</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>RA</given-names>
              </name>
              <collab>CHAMPION PHOENIX Investigators</collab>
            </person-group>
            <article-title>Effect of platelet inhibition with cangrelor during PCI on ischemic events.</article-title>
            <source>N Engl J Med</source>
            <year>2013</year>
            <month>Apr</month>
            <day>04</day>
            <volume>368</volume>
            <issue>14</issue>
            <fpage>1303</fpage>
            <page-range>1303-13</page-range>
            <pub-id pub-id-type="pmid">23473369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peterson</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Hamm</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Leonardi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prats</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Deliargyris</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION.</article-title>
            <source>Circ Cardiovasc Interv</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>e011069</fpage>
            <pub-id pub-id-type="pmid">35196863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Lincoff</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>McNulty</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Montalescot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kleiman</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Pollack</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Manoukian</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Widimsky</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chew</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Cura</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Manukov</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tousek</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jafar</surname>
                <given-names>MZ</given-names>
              </name>
              <name>
                <surname>Arneja</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Skerjanec</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>RA</given-names>
              </name>
              <collab>CHAMPION PLATFORM Investigators</collab>
            </person-group>
            <article-title>Intravenous platelet blockade with cangrelor during PCI.</article-title>
            <source>N Engl J Med</source>
            <year>2009</year>
            <month>Dec</month>
            <day>10</day>
            <volume>361</volume>
            <issue>24</issue>
            <fpage>2330</fpage>
            <page-range>2330-41</page-range>
            <pub-id pub-id-type="pmid">19915222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rollini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Franchi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tello-Montoliu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Darlington</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferreiro</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;iz-Lozano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zenni</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Guzman</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Bass</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Angiolillo</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.</article-title>
            <source>JACC Cardiovasc Interv</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>426</fpage>
            <page-range>426-34</page-range>
            <pub-id pub-id-type="pmid">24630878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Writing Committee Members</collab>
              <name>
                <surname>Lawton</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Tamis-Holland</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Bangalore</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Beckie</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Bischoff</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bittl</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>DiMaio</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Don</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Fremes</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Gaudino</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Goldberger</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Jaswal</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Kurlansky</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Mehran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Metkus</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Nnacheta</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Sellke</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yong</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Zwischenberger</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint&#x000a0;Committee&#x000a0;on&#x000a0;Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2022</year>
            <month>Jan</month>
            <day>18</day>
            <volume>79</volume>
            <issue>2</issue>
            <fpage>e21</fpage>
            <page-range>e21-e129</page-range>
            <pub-id pub-id-type="pmid">34895950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Luca</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Capodanno</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Angiolillo</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2021</year>
            <month>Jul</month>
            <day>06</day>
            <volume>10</volume>
            <issue>13</issue>
            <fpage>e022125</fpage>
            <pub-id pub-id-type="pmid">34212768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaduganathan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Deliargyris</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Hamm</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Menozzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Prats</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Elkin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <collab>CHAMPION Investigators</collab>
            </person-group>
            <article-title>Cangrelor With and Without Glycoprotein&#x000a0;IIb/IIIa Inhibitors in&#x000a0;Patients&#x000a0;Undergoing Percutaneous&#x000a0;Coronary Intervention.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2017</year>
            <month>Jan</month>
            <day>17</day>
            <volume>69</volume>
            <issue>2</issue>
            <fpage>176</fpage>
            <page-range>176-185</page-range>
            <pub-id pub-id-type="pmid">28081827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ubaid</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Wrigley</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Armesilla</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Townend</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Khogali</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Munir</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Martins</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hothi</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>McAlindon</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Cotton</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial.</article-title>
            <source>Thromb Haemost</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>119</volume>
            <issue>7</issue>
            <fpage>1171</fpage>
            <page-range>1171-1181</page-range>
            <pub-id pub-id-type="pmid">31129911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Hamm</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Leonardi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Skerjanec</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Iwaoka</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Stuckey</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Gogia</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Gruberg</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>RA</given-names>
              </name>
              <collab>CHAMPION Investigators</collab>
            </person-group>
            <article-title>Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data.</article-title>
            <source>Lancet</source>
            <year>2013</year>
            <month>Dec</month>
            <day>14</day>
            <volume>382</volume>
            <issue>9909</issue>
            <fpage>1981</fpage>
            <page-range>1981-92</page-range>
            <pub-id pub-id-type="pmid">24011551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abtan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Hamm</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Abnousi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Prats</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Deliargyris</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <collab>CHAMPION PHOENIX Investigators</collab>
            </person-group>
            <article-title>Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute&#x000a0;Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.</article-title>
            <source>JACC Cardiovasc Interv</source>
            <year>2016</year>
            <month>Sep</month>
            <day>26</day>
            <volume>9</volume>
            <issue>18</issue>
            <fpage>1905</fpage>
            <page-range>1905-13</page-range>
            <pub-id pub-id-type="pmid">27659566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gargiulo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Esposito</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cirillo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nagler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Minuz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Campo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gragnano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Manavifar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Piccolo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Avvedimento</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tebaldi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wahl</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hunziker</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Billinger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Windecker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Valgimigli</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale : The FABOLUS FASTER Trial.</article-title>
            <source>J Cardiovasc Transl Res</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>110</fpage>
            <page-range>110-119</page-range>
            <pub-id pub-id-type="pmid">32096064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akers</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Oestreich</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Ferraris</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wethington</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Steinhubl</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>50</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-35</page-range>
            <pub-id pub-id-type="pmid">19779037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Voeltz</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Manoukian</surname>
                <given-names>SV</given-names>
              </name>
            </person-group>
            <article-title>Cangrelor in patients undergoing cardiac surgery: the BRIDGE study.</article-title>
            <source>Expert Rev Cardiovasc Ther</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>11</volume>
            <issue>7</issue>
            <fpage>811</fpage>
            <page-range>811-6</page-range>
            <pub-id pub-id-type="pmid">23895024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schneider</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Seecheran</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Gogo</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pharmacodynamic effects during the transition between cangrelor and ticagrelor.</article-title>
            <source>JACC Cardiovasc Interv</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>435</fpage>
            <page-range>435-42</page-range>
            <pub-id pub-id-type="pmid">24656538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baker</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Ingram</surname>
                <given-names>KT</given-names>
              </name>
            </person-group>
            <article-title>Cangrelor.</article-title>
            <source>Hosp Pharm</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>50</volume>
            <issue>10</issue>
            <fpage>922</fpage>
            <page-range>922-929</page-range>
            <pub-id pub-id-type="pmid">27729681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bairey Merz</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Bello</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Duvernoy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Elgendy</surname>
                <given-names>IY</given-names>
              </name>
              <name>
                <surname>Ferdinand</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Hameed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Itchhaporia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Minissian</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>RU</given-names>
              </name>
              <name>
                <surname>Volgman</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wenger</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Pepine</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Lindley</surname>
                <given-names>KJ</given-names>
              </name>
              <collab>American College of Cardiology Cardiovascular Disease in Women Committee and the Cardio-Obstetrics Work Group</collab>
            </person-group>
            <article-title>Management of Women With Acquired Cardiovascular Disease From Pre-Conception Through Pregnancy and&#x000a0;Postpartum: JACC Focus Seminar 3/5.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2021</year>
            <month>Apr</month>
            <day>13</day>
            <volume>77</volume>
            <issue>14</issue>
            <fpage>1799</fpage>
            <page-range>1799-1812</page-range>
            <pub-id pub-id-type="pmid">33832606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cavender</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Hamm</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Prats</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Elkin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Deliargyris</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>RA</given-names>
              </name>
              <collab>CHAMPION PHOENIX Investigators*</collab>
            </person-group>
            <article-title>Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIX.</article-title>
            <source>Circ Cardiovasc Interv</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>10</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">28801539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Firstenberg</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Dyke</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Angiolillo</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Ramaiahm</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brtko</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Welsby</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Chandna</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Voeltz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tummala</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hutyra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Manoukian</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Prats</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Todd</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chronos</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dietrich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Montalescot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Topo</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery.</article-title>
            <source>Heart Surg Forum</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>E60</fpage>
            <page-range>E60-9</page-range>
            <pub-id pub-id-type="pmid">23625478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parker</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Prats</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>JRS</given-names>
              </name>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Hamm</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Storey</surname>
                <given-names>RF</given-names>
              </name>
              <collab>CHAMPION PHOENIX Investigators</collab>
            </person-group>
            <article-title>Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.</article-title>
            <source>Thromb Haemost</source>
            <year>2017</year>
            <month>Jun</month>
            <day>02</day>
            <volume>117</volume>
            <issue>6</issue>
            <fpage>1093</fpage>
            <page-range>1093-1100</page-range>
            <pub-id pub-id-type="pmid">28382371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaduganathan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Deliargyris</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Hamm</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Menozzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Prats</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Elkin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials.</article-title>
            <source>JAMA Cardiol</source>
            <year>2017</year>
            <month>Feb</month>
            <day>01</day>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>127</fpage>
            <page-range>127-135</page-range>
            <pub-id pub-id-type="pmid">27902833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rollini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Franchi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Angiolillo</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Drug-Drug Interactions When Switching&#x000a0;Between Intravenous and Oral&#x000a0;P2Y<sub>12</sub> Receptor Inhibitors: How Real Is It?</article-title>
            <source>JACC Cardiovasc Interv</source>
            <year>2017</year>
            <month>Jan</month>
            <day>23</day>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>130</fpage>
            <page-range>130-132</page-range>
            <pub-id pub-id-type="pmid">28104205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Franchi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ortega-Paz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rollini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Galli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Been</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ghanem</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shalhoub</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ossi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rivas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Pineda</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Suryadevara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Soffer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zenni</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Reiter</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jilma</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Angiolillo</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Cangrelor in Patients With Coronary Artery Disease Pretreated With&#x000a0;Ticagrelor: The Switching Antiplatelet (SWAP)-5 Study.</article-title>
            <source>JACC Cardiovasc Interv</source>
            <year>2023</year>
            <month>Jan</month>
            <day>09</day>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>36</fpage>
            <page-range>36-46</page-range>
            <pub-id pub-id-type="pmid">36317958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schneider</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Seecheran</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Raza</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Gogo</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pharmacodynamic effects during the transition between cangrelor and prasugrel.</article-title>
            <source>Coron Artery Dis</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>42</fpage>
            <page-range>42-8</page-range>
            <pub-id pub-id-type="pmid">25089928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Angiolillo</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Rollini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Storey</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Sibbing</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>So</surname>
                <given-names>DYF</given-names>
              </name>
              <name>
                <surname>Trenk</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alexopoulos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gurbel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Hochholzer</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>De Luca</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bonello</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Aradi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cuisset</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tantry</surname>
                <given-names>US</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Valgimigli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Waksman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mehran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Montalescot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Franchi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>International Expert Consensus on Switching Platelet P2Y<sub>12</sub> Receptor-Inhibiting Therapies.</article-title>
            <source>Circulation</source>
            <year>2017</year>
            <month>Nov</month>
            <day>14</day>
            <volume>136</volume>
            <issue>20</issue>
            <fpage>1955</fpage>
            <page-range>1955-1975</page-range>
            <pub-id pub-id-type="pmid">29084738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leonardi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Practical considerations for cangrelor use in patients with acute coronary syndromes.</article-title>
            <source>Eur Heart J Acute Cardiovasc Care</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-44</page-range>
            <pub-id pub-id-type="pmid">28574274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greenbaum</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Ohman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Borzak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stebbins</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Le May</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Stankowski</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Emanuelsson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Weaver</surname>
                <given-names>WD</given-names>
              </name>
            </person-group>
            <article-title>Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial.</article-title>
            <source>Am Heart J</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>154</volume>
            <issue>4</issue>
            <fpage>702</fpage>
            <page-range>702-9</page-range>
            <pub-id pub-id-type="pmid">17892995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deeks</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Duggan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Abrocitinib: First Approval.</article-title>
            <source>Drugs</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>81</volume>
            <issue>18</issue>
            <fpage>2149</fpage>
            <page-range>2149-2157</page-range>
            <pub-id pub-id-type="pmid">34807428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lupercio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Giancaterino</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Villablanca</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hoffmayer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Raissi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Krummen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Birgersdotter-Green</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Feld</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Reeves</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mahmud</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>P2Y<sub>12</sub> inhibitors with oral anticoagulation for percutaneous coronary intervention with atrial fibrillation: a systematic review and meta-analysis.</article-title>
            <source>Heart</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>106</volume>
            <issue>8</issue>
            <fpage>575</fpage>
            <page-range>575-583</page-range>
            <pub-id pub-id-type="pmid">32034008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Angiolillo</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Saucedo</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Shaburishvili</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Prats</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.</article-title>
            <source>J Thromb Thrombolysis</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-55</page-range>
            <pub-id pub-id-type="pmid">22569899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horlocker</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Vandermeuelen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Gogarten</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Leffert</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Benzon</surname>
                <given-names>HT</given-names>
              </name>
            </person-group>
            <article-title>Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition).</article-title>
            <source>Reg Anesth Pain Med</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>263</fpage>
            <page-range>263-309</page-range>
            <pub-id pub-id-type="pmid">29561531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anton-Martin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Matherne</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rayburn</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cangrelor Dosing and Monitoring for Prevention of Acute Systemic-to-Pulmonary Artery Shunt Thrombosis in Neonates.</article-title>
            <source>J Pediatr Pharmacol Ther</source>
            <year>2022</year>
            <volume>27</volume>
            <issue>8</issue>
            <fpage>707</fpage>
            <page-range>707-714</page-range>
            <pub-id pub-id-type="pmid">36415767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Whellan</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Lambe</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bellibas</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Wijngaard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Prats</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Krucoff</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>Electrocardiographic safety of cangrelor, a new intravenous antiplatelet agent: a randomized, double-blind, placebo- and moxifloxacin-controlled thorough QT study.</article-title>
            <source>J Cardiovasc Pharmacol</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>62</volume>
            <issue>5</issue>
            <fpage>466</fpage>
            <page-range>466-78</page-range>
            <pub-id pub-id-type="pmid">23921301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Angiolillo</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Hamm</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Prats</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials.</article-title>
            <source>J Thromb Thrombolysis</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>40</volume>
            <issue>3</issue>
            <fpage>317</fpage>
            <page-range>317-22</page-range>
            <pub-id pub-id-type="pmid">26024789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stolldorf</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Deployment of rapid response teams by 31 hospitals in a statewide collaborative.</article-title>
            <source>Jt Comm J Qual Patient Saf</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>41</volume>
            <issue>4</issue>
            <fpage>186</fpage>
            <page-range>186-91</page-range>
            <pub-id pub-id-type="pmid">25977203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156148.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rymer</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Angiolillo</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garratt</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Waksman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tasissa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Salahuddin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>El-Sabae</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dell'Anna</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Davidson-Ray</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Washam</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Ohman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>TY</given-names>
              </name>
            </person-group>
            <article-title>Cangrelor Use Patterns and Transition to Oral P2Y<sub>12</sub> Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO Registry.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2022</year>
            <month>Jun</month>
            <day>07</day>
            <volume>11</volume>
            <issue>11</issue>
            <fpage>e024513</fpage>
            <pub-id pub-id-type="pmid">35621210</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
